New drug cocktail takes on deadly brain cancer

NCT ID NCT07391215

Recruiting now Disease control Sponsor: Institute of Cancer Research, United Kingdom Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a new drug called paxalisib combined with standard chemotherapy (temozolomide) in people with high-grade brain tumours like glioblastoma. The goal is to find a safe dose and see if the combination can slow tumour growth. About 64 participants will be enrolled, and the trial is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: paxalisib (a targeted drug) combined with temozolomide (chemotherapy)
What this could lead to: If successful, this combination could offer a new treatment option for people with aggressive brain tumours, potentially slowing disease progression.
What could go wrong: This is an early-phase trial with only 64 participants, so results may not apply broadly. The combination may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME (GBM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma susceptibility 1 malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA MULTIFORME (GBM) MALIGNANT PRIMARY GLIOMAS

Contacts and locations

Locations

Royal Marden NHS Foundation Trust
RECRUITING

Sutton, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.